CL2021000687A1 - Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina - Google Patents
Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxinaInfo
- Publication number
- CL2021000687A1 CL2021000687A1 CL2021000687A CL2021000687A CL2021000687A1 CL 2021000687 A1 CL2021000687 A1 CL 2021000687A1 CL 2021000687 A CL2021000687 A CL 2021000687A CL 2021000687 A CL2021000687 A CL 2021000687A CL 2021000687 A1 CL2021000687 A1 CL 2021000687A1
- Authority
- CL
- Chile
- Prior art keywords
- modified release
- preparation
- dosage form
- oral dosage
- multiple unit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada que comprende una pluralidad de pellets de liberación modificada de doxilamina o una sal de la misma y una pluralidad de pellets de liberación modificada de piridoxina o una sal de la misma, en el que el procedimiento comprende recubrir los pellets de doxilamina que tienen la capa de recubrimiento activa interna y la capa de recubrimiento entérico intermedia y los pellets de piridoxina que tienen la capa de recubrimiento activa interna, en el que la etapa de recubrimiento comprende la pulverización simultánea de una mezcla que comprende los agentes de recubrimiento de liberación entérica y modificada y la adición de agentes formadores de poros en forma de polvo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18382687.4A EP3628311B1 (en) | 2018-09-27 | 2018-09-27 | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000687A1 true CL2021000687A1 (es) | 2021-08-06 |
Family
ID=63722327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000687A CL2021000687A1 (es) | 2018-09-27 | 2021-03-19 | Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP3628311B1 (es) |
JP (1) | JP7444862B2 (es) |
KR (1) | KR20210066864A (es) |
CN (1) | CN112839638B (es) |
AR (1) | AR116480A1 (es) |
AU (1) | AU2019348630B2 (es) |
BR (1) | BR112021005192A8 (es) |
CL (1) | CL2021000687A1 (es) |
CO (1) | CO2021005412A2 (es) |
CR (1) | CR20210208A (es) |
CY (1) | CY1123785T1 (es) |
DK (1) | DK3628311T3 (es) |
DO (1) | DOP2021000052A (es) |
EA (1) | EA202190700A1 (es) |
EC (1) | ECSP21029863A (es) |
ES (1) | ES2847648T3 (es) |
HR (1) | HRP20210181T1 (es) |
HU (1) | HUE053082T2 (es) |
MX (1) | MX2021003357A (es) |
MY (1) | MY197676A (es) |
NI (1) | NI202100021A (es) |
PE (1) | PE20211462A1 (es) |
PH (1) | PH12021550640A1 (es) |
PL (1) | PL3628311T3 (es) |
PT (1) | PT3628311T (es) |
RS (1) | RS61368B1 (es) |
SA (1) | SA521421557B1 (es) |
SI (1) | SI3628311T1 (es) |
UA (1) | UA127768C2 (es) |
WO (1) | WO2020064985A1 (es) |
ZA (1) | ZA202101279B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
BRPI0711606A2 (pt) * | 2006-05-22 | 2012-02-14 | Teva Pharma | formulações de hidrocloreto de duloxetina de liberação retardada |
WO2010037849A1 (en) * | 2008-10-02 | 2010-04-08 | Laboratorios Del Dr. Esteve, S.A. | Duloxetine enteric pellets |
CA2761212A1 (en) * | 2011-12-07 | 2013-06-07 | Pharmascience Inc. | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing |
WO2013123569A1 (en) | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
MX355912B (es) * | 2012-02-22 | 2018-05-04 | Duchesnay Inc | Formulación de doxilamina y piridoxina y/o sus metabolitos o sales. |
CN103142552A (zh) * | 2013-02-22 | 2013-06-12 | 广州科的信医药技术有限公司 | 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法 |
CN103690506B (zh) * | 2013-11-08 | 2015-05-13 | 舒泰神(北京)生物制药股份有限公司 | 一种曲司氯铵缓释组合物及其制备方法 |
HUE038969T2 (hu) | 2014-08-29 | 2018-12-28 | Duchesnay Inc | A doxilamin és piridoxin és/vagy metabolitjai vagy sói plurimodális felszabadulású kiszerelési formája |
HUE049247T2 (hu) * | 2014-11-26 | 2020-09-28 | Evonik Operations Gmbh | Etanol hatásával szemben ellenálló gyógyászati vagy táplálék-gyógyszerészeti kompozíció |
CN106606502B (zh) * | 2015-10-27 | 2019-12-31 | 四川海思科制药有限公司 | 一种琥珀酸多西拉敏盐酸吡哆醇肠溶片药物组合物及其制备方法 |
-
2018
- 2018-09-27 RS RS20210089A patent/RS61368B1/sr unknown
- 2018-09-27 PT PT183826874T patent/PT3628311T/pt unknown
- 2018-09-27 PL PL18382687T patent/PL3628311T3/pl unknown
- 2018-09-27 DK DK18382687.4T patent/DK3628311T3/da active
- 2018-09-27 HU HUE18382687A patent/HUE053082T2/hu unknown
- 2018-09-27 SI SI201830208T patent/SI3628311T1/sl unknown
- 2018-09-27 ES ES18382687T patent/ES2847648T3/es active Active
- 2018-09-27 EP EP18382687.4A patent/EP3628311B1/en active Active
-
2019
- 2019-09-23 AR ARP190102692A patent/AR116480A1/es unknown
- 2019-09-27 WO PCT/EP2019/076140 patent/WO2020064985A1/en active Application Filing
- 2019-09-27 MY MYPI2021001522A patent/MY197676A/en unknown
- 2019-09-27 KR KR1020217012326A patent/KR20210066864A/ko not_active Application Discontinuation
- 2019-09-27 EA EA202190700A patent/EA202190700A1/ru unknown
- 2019-09-27 BR BR112021005192A patent/BR112021005192A8/pt unknown
- 2019-09-27 JP JP2021516918A patent/JP7444862B2/ja active Active
- 2019-09-27 AU AU2019348630A patent/AU2019348630B2/en active Active
- 2019-09-27 MX MX2021003357A patent/MX2021003357A/es unknown
- 2019-09-27 UA UAA202101817A patent/UA127768C2/uk unknown
- 2019-09-27 PE PE2021000345A patent/PE20211462A1/es unknown
- 2019-09-27 CN CN201980063235.6A patent/CN112839638B/zh active Active
- 2019-09-27 CR CR20210208A patent/CR20210208A/es unknown
-
2021
- 2021-01-27 CY CY20211100065T patent/CY1123785T1/el unknown
- 2021-02-02 HR HRP20210181TT patent/HRP20210181T1/hr unknown
- 2021-02-25 ZA ZA2021/01279A patent/ZA202101279B/en unknown
- 2021-03-19 PH PH12021550640A patent/PH12021550640A1/en unknown
- 2021-03-19 CL CL2021000687A patent/CL2021000687A1/es unknown
- 2021-03-23 NI NI202100021A patent/NI202100021A/es unknown
- 2021-03-24 SA SA521421557A patent/SA521421557B1/ar unknown
- 2021-03-26 DO DO2021000052A patent/DOP2021000052A/es unknown
- 2021-04-26 CO CONC2021/0005412A patent/CO2021005412A2/es unknown
- 2021-04-26 EC ECSENADI202129863A patent/ECSP21029863A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016000117A1 (es) | Autotaxina inhibidores comprende un anillo heteroaromático-bencilamina ciclo basico | |
CL2015001891A1 (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas; uso para tratar el dolor; y metodo de preparacion. (divisional de la solicitud n°2754-2014). | |
AR122580A2 (es) | Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales | |
CL2014000131A1 (es) | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada que comprende pirfenidona; y su uso para el tratamiento o regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica. | |
BR112012024019A2 (pt) | forma de dosagem de liberação controlada, e, método para liberar uma droga | |
CL2011000935A1 (es) | Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor. | |
AR098417A1 (es) | Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatina | |
AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
AR083528A1 (es) | Analogos de peptido insulinotropico dependiente de glucosa | |
CL2015000375A1 (es) | Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras. | |
CO2021005412A2 (es) | Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina | |
CR20190144A (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
JP2012082195A5 (es) | ||
AR105758A1 (es) | Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidona | |
MX2021003033A (es) | Formulaciones de compuestos de cicloserina y aplicaciones de estas. | |
ES2803957R1 (es) | Una mezcla de oxido de grafeno reducido, matriz polimerica que contiene el mismo y un procedimiento para su preparacion | |
ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
UY38028A (es) | Combinación farmacéutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y su uso para el tratamiento del dolor | |
AR121619A1 (es) | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación | |
EP3813801A4 (en) | OSMOTIC EXTENDED RELEASE TABLET DOSAGE FORM WITH METFORMIN AND SITAGLIPTIN | |
BR112017004190A2 (pt) | ?formulação de liberação plurimodal de doxilamina e piridoxina e/ou metabolitos ou sais da mesma?. | |
TH164080B (th) | รูปเเบบยาของเเข็ง | |
TH135292B (th) | องค์ประกอบทางเภสัชกรรม |